We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Lung Cancer

Journal Scan / Research · February 17, 2021

cfDNA Noninferior to Standard of Care Tissue Testing in Advanced NSCLC

Journal of Clinical Oncology


Additional Info

Journal of Clinical Oncology
Biomarker Discovery and Outcomes for Comprehensive Cell-Free Circulating Tumor DNA Versus Standard-of-Care Tissue Testing in Advanced Non-Small-Cell Lung Cancer
J. Clin. Oncol 2021 Jan 11;5(1)93-102, R Palmero, A Taus, S Viteri, et al

Further Reading